Gail T Louis
Overview
Explore the profile of Gail T Louis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen D, Davis B, Simpson L, Cushman W, Cutler J, Dobre M, et al.
Clin Nephrol
. 2016 Dec;
87 (2017)(1):11-20.
PMID: 27900942
Background/objectives: Chronic kidney disease (CKD) and cancer are both common in older patients; whether CKD increases risk for cancer is unclear. This study evaluated CKD as a risk factor for...
2.
Puttnam R, Davis B, Pressel S, Whelton P, Cushman W, Louis G, et al.
JAMA Intern Med
. 2016 Nov;
177(1):67-76.
PMID: 27893045
Importance: On the basis of observational studies, the use of thiazide diuretics for the treatment of hypertension is associated with reduced fracture risk compared with nonuse. Data from randomized clinical...
3.
Muntner P, Whittle J, Lynch A, Colantonio L, Simpson L, Einhorn P, et al.
Ann Intern Med
. 2015 Jul;
163(5):329-38.
PMID: 26215765
Background: Variability of blood pressure (BP) across outpatient visits is frequently dismissed as random fluctuation around a patient's underlying BP. Objective: To examine the association of visit-to-visit variability (VVV) of...
4.
Rahman M, Baimbridge C, Davis B, Barzilay J, Basile J, Henriquez M, et al.
Clin Nephrol
. 2013 Jul;
80(4):235-48.
PMID: 23816477
Background/aims: The role of statins in preventing cardiovascular outcomes in patients with chronic kidney disease (CKD) is unclear. This paper compares cardiovascular outcomes with pravastatin vs. usual care, stratified by...
5.
Cushman W, Ford C, Einhorn P, Wright Jr J, Preston R, Davis B, et al.
J Clin Hypertens (Greenwich)
. 2008 Dec;
10(10):751-60.
PMID: 19090876
Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9 years) by randomized groups: chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40...
6.
Rahman M, Baimbridge C, Davis B, Barzilay J, Basile J, Henriquez M, et al.
Am J Kidney Dis
. 2008 Aug;
52(3):412-24.
PMID: 18676075
Background: Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear. Study Design: Prospective randomized clinical trial, post...
7.
Wright Jr J, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis C, et al.
Arch Intern Med
. 2008 Jan;
168(2):207-17.
PMID: 18227370
Background: Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcomes by race in hypertensive individuals with and without...
8.
Rahman M, Pressel S, Davis B, Nwachuku C, Wright Jr J, Whelton P, et al.
Ann Intern Med
. 2006 Feb;
144(3):172-80.
PMID: 16461961
Background: Chronic kidney disease is common in older patients with hypertension. Objective: To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular...
9.
Whelton P, Barzilay J, Cushman W, Davis B, Iiamathi E, Kostis J, et al.
Arch Intern Med
. 2005 Jun;
165(12):1401-9.
PMID: 15983290
Background: Optimal first-step antihypertensive drug therapy in type 2 diabetes mellitus (DM) or impaired fasting glucose levels (IFG) is uncertain. We wished to determine whether treatment with a calcium channel...
10.
Rahman M, Pressel S, Davis B, Nwachuku C, Wright Jr J, Whelton P, et al.
Arch Intern Med
. 2005 Apr;
165(8):936-46.
PMID: 15851647
Background: This study was performed to determine whether, in high-risk hypertensive patients with a reduced glomerular filtration rate (GFR), treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor...